Exercise of Share Options by a Person Discharging Managerial Responsibilities // Chi-Med
News Archive
Previous Article   |   Next Article
Regulatory Notice, RNS Announcements | 30 Nov 2016

Exercise of Share Options by a Person Discharging Managerial Responsibilities

London: Wednesday, November 30, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Weiguo Su, Executive Vice President and Chief Scientific Officer (being a Person Discharging Managerial Responsibilities), has exercised 25,535 share options (granted in 2007 and which are soon due to expire in May 2017) over ordinary shares of US$1.00 each in Chi-Med (the “Ordinary Shares”) at an exercise price of GBP1.535 per share on November 25, 2016. Such Ordinary Shares will be held in the form of American Depositary Shares (“ADSs”) each representing one half of one Ordinary Share.

Following the above exercise of options and subject to the completion of allotment, the holding of Dr Su is 25,535 Ordinary Shares, representing approximately 0.04% of the current issued share capital of Chi-Med, which he intends to hold as a long term investment. Additionally Dr Su holds a further 300,000 unexercised options which would represent a further 0.49% of the issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name  Dr Weiguo Su

2

Reason for the notification

a)

Position/status Executive Vice President and Chief Scientific Officer of Chi-Med

b)

Initial notification/Amendment  Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name  Hutchison China MediTech Limited

b)

LEI  N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument Identification code

Ordinary Shares of US$1.00 each in the form of ADSs each representing one half of one Ordinary Share of US$1.00

DI ISIN: KYG4672N1016
ADS ISIN: US44842L1035

b)

Nature of the transaction Exercise of share options on November 25, 2016 at a price of GBP1.535 per share. Such Ordinary Shares will be held in the form of ADSs.

c)

 Price(s) and volume(s)
Price(s) Volume(s)
GBP1.535 25,535

d)

Aggregated information — Aggregate volume
— Price
Aggregated volume: 25,535
Price information: GBP1.535

e)

 Date of the transaction 2016-11-25

f)

 Place of the transaction Outside a trading venue

 

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

Contacts

Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle,
Citigate Dewe Rogerson
+44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com

David Dible,

Citigate Dewe Rogerson

+44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500